Global Gastrointestinal Cancer Drugs Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|胃腸癌治療藥的全球市場:2020年∼2027年 Global Gastrointestinal Cancer Drugs Market - 2020-2027|
|出版日期: 2021年05月10日||內容資訊: 英文 180 Pages||
The global gastrointestinal cancer drugs market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Gastrointestinal cancer is a term that includes a group of cancers, an abnormal condition of the gastrointestinal tract and associated organs of the digestive system, which comprises the esophagus, stomach, pancreas, biliary system, small intestine, large intestine, rectum, and anus. The exact cause of many types of gastrointestinal cancer is unknown. Still, risk factors for gastrointestinal cancer include smoking, alcohol consumption, obesity, chronic pancreatitis. The symptoms of gastrointestinal cancer depend on the affected organ. They include obstruction (resulting in difficulty swallowing or excreting), unusual bleeding, or other related problems. Gastrointestinal cancer is diagnosed as the type of cancer that is suspected. Lab tests, imaging tests, biopsies, and endoscopy are the methods of diagnosing many types of cancer. The treatment methods depend on the type of cancer, stage, and other general health factors. Standard methods of treating gastrointestinal cancer include surgery (most commonly used), chemotherapy, Targeted therapy and radiation therapy.
The global gastrointestinal cancer drugs market growth is driven by the growing prevalence of gastrointestinal cancer, rise in demand for targeted drug therapy, rise in public awareness, government initiatives to eliminate cancer, and changing lifestyle, increasing obesity cases.
Growing prevalence of gastrointestinal cancer cases, is expected to drive the growth in the forecast period
As per the data from GLOBOCAN, there were an estimated 4.8 million new cases of gastrointestinal (GI) cancers and 3.4 million related deaths, worldwide, in 2018. GI cancers account for 26% of the global cancer incidence. The American Cancer Society's estimates for stomach cancer (also known as gastric cancer) in the United States for 2021 are about 26,560 new cases of stomach cancer (16,160 in men and 10,400 in women).
Increasing FDA approvals and developing pipeline of new drugs, is expected to drive the growth in the forecast period
For instance, in January 2019, the U.S. FDA approved Samsung Bioepis drug Ontruzant (trastuzumab biosimilar) to treat metastatic gastric cancer gastroesophageal junction adenocarcinoma.
Also, Bristol-Meyer Squibb's Opdivo (Nivolumab) intravenous infusion injection is in the development pipeline. It is in phase 3 for treatment of gastric cancer, Gastroesophageal cancer.
Major side effects of drugs is likely to hinder the market growth
The major hampering factors for the growth of the global gastrointestinal cancer drugs market are the severe side effects caused by the drugs. These include nausea and vomiting, confusion, loss of appetite and weight loss, Drowsiness, fatigue, diarrhea, hair loss, sore mouth, hand-foot syndrome, low blood cell counts, blood clots (Deep Vein Thrombosis), nervous system damage, and heart damage in patients undergoing treatment for stomach cancer. According to 2017 the American Cancer Society (ACS) report on side effects of stomach cancer, chemotherapy drugs such as doxorubicin and epirubicin can cause permanent damage to the heart if used for a long time or in high doses.
COVID-19 Impact Analysis
Due to the covid-19 pandemic outbreak, the market for Global differentiated thyroid cancer drugs market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the Drugs were manufactured less compared to previous years, during the outbreak.
Based on the Therapy, the global gastrointestinal cancer drugs market is segmented into Chemotherapy, Targeted therapy (Sunitinib, Trastuzumab, Imatinib), Radiation therapy, Surgery and Others.
Targeted therapy (Sunitinib, Trastuzumab, Imatinib) segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)
Some drugs can target specific proteins in gastrointestinal tumor (GI) cells that help them to divide and grow. These targeted drugs also called precision drugs, are often beneficial in treating GI cancers and, these drugs work differently from standard chemotherapy drugs, which are usually not helpful. The targeted drugs used to treat GI cancers are called Tyrosine kinase inhibitors (TKIs) because they target proteins that are tyrosine kinases, such as KIT and PDGFRA.
Sunitinib is a targeted drug of indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic property. It is sold under the brand name Sutent. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. Sunitinib is used to treat specific types of advanced or progressive tumors of the stomach, intestines, esophagus, pancreas, or kidneys.
Trastuzumab, sold under the brand name called Herceptin which is a recombinant IgG1 monoclonal antibody. It works against the HER2 (human epidermal growth factor receptor protein) receptors which are responsible for the uncontrolled proliferation of cancer cells in stomach cancer cells. It destroys the cancer cells by inhibiting HER2. It also inhibits various cancer-causing downstream signaling pathways. It is also used in breast cancer treatment.
Imatinib is a targeted cancer drug and is also known by its brand name Gleevec. It is a member of the small molecule tyrosine kinase inhibitors class with selectivity for the Abl kinase is a potent competitive inhibitor of ATP binding to Abl kinase and the c-Kit and PDGF receptor tyrosine kinases. This drug is used to treat most people with GI cancers at some point. This drug targets both the KIT and PDGFRA proteins, blocking their ability to help tumor cells grow and divide.
Based on End-User, the global gastrointestinal Cancer drugs market is segmented into Hospitals, Cancer Research centers, Clinics, Ambulatory surgical centers and Others.
Due to the growing patient population, the hospitals segment held the largest market share. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment. Also the medications can only be administrated by intravenously and surgery is done under supervision of medical practioners at these locations.
North America holds the largest market in the global gastrointestinal cancer drugs market due to the high incidence of cancer, according to the International Agency for Research on Cancer (IARC), which claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and targeted therapy drugs, the total availability of advanced technological tools, FDA approval of new drugs and also the presence of a vast number of organizations engaged in R&D activities related to cancer vaccines.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For example, in 2017, Biocon Ltd., in partnership with Mylan N.V., received FDA approval for Ogivri (trastuzumab) to treat stomach cancer gastro-esophageal junction adenocarcinoma. Ogivri is the first FDA-approved biosimilar of Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the U.S.
The Global Gastrointestinal Cancer Drugs Market is quite competitive with some key competitors like Amgen Limited & Amgen Ireland Limited, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Johnson & Johnson Private Limited, GlaxoSmithKline plc., Celgene Corporation, Pfizer Inc., and Novartis AG, Sanofi. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the market's growth globally. For instance, In March 2019, Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) approval of TRAZIMERA (trastuzumab), a biosimilar of Herceptin (trastuzumab), for the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Company Overview: Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world. It is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA). It has 110,000 (2020) total employees and generates $48.66 billion (2020) revenue.
Product Portfolio: The company portfolio includes Oncology, Cardiovascular, Renal and Metabolic Medicine, Immunology, Dermatology, Ophthalmology, Neuroscience, Respiratory and Others.
Novartis AG is developing NIS793, spartalizumab is a TGFB1 Inhibitor drug to treat patients with Pancreatic Cancer is under Phase 2 clinical trials expected to complete by 2025.
The global gastrointestinal cancer drugs market report would provide an access to an approx. 53 market data table, 46 figures and 240 pages.
LIST NOT EXHAUSTIVE